Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/ KEYNOTE-775 Meeting Abstract
| Authors: | Colomba, E.; Lorusso, D.; Mackay, H.; Moore, R.; Yonemori, K.; Kim, Y. M.; Sanli, U. A.; Xie, R.; Barresi, G.; McKenzie, J.; Makker, V. |
| Abstract Title: | Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/ KEYNOTE-775 |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S512 |
| End Page: | S513 |
| Language: | English |
| ACCESSION: | WOS:001087480201089 |
| DOI: | 10.1016/j.annonc.2023.09.1927 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 748P -- Source: Wos |
